Should you detach from Eyegate Pharmaceuticals Inc. (NASDAQ:EYEG)?

959

Eyegate Pharmaceuticals, Inc. (NASDAQ:EYEG) has posted results for the last fiscal year, recording EPS of $-1.48. For this year, EPS is anticipated to grow 44.00% over the preceding year, while next year’s EPS is predicted to increase 163.30%.

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction. Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend. The market is approaching oversold territory. Be watchful of a trend reversal.

Shares of Eyegate Pharmaceuticals, Inc. are now trading at $1.39, giving it market cap of $16.22M. Over the last 12 months, shares of Eyegate Pharmaceuticals, Inc. have risen to maximum of $-64.36% and declined to a minimum of $25.23%.

Eyegate Pharmaceuticals, Inc. shows 20-Day Simple Moving Average of $-25.45% and 50-Day Simple Moving Average of $-31.53%. The 200-Day SMA is $-25.26%.

The stock’s weekly performance is -27.60% while its monthly performance is -22.78%. Year-to-date the equity has moved -14.72% compared to a performance of -55.45% over the preceding 12 months.

Eyegate Pharmaceuticals, Inc. has witnessed – insider transactions, showing insider ownership of 17.80%. That compares to 8.10% ownership by institutional investors after -2.78% institutional transactions.

Return on investments in Eyegate Pharmaceuticals, Inc. for the last 12 months is 4448.90%, while return on assets for the equivalent period is -122.50%. Return on equity for the previous 12 months, on the other hand, is -671.10%.

Eyegate Pharmaceuticals, Inc. has RSI (Relative Strength Index) of 25.20.

EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a specialty pharmaceutical company that focuses on developing and commercializing products for treating diseases and disorders of the eye, announced today the pricing of a public offering of an aggregate of 6,666,667 shares of common stock (or common stock equivalents) and warrants to purchase an aggregate of 6,666,667 shares of common stock with expected total gross proceeds of $10.0 million. The offering is expected to close on or about June 14, 2017, subject to satisfaction of customary closing conditions.

Subscribe to get your free report!

* indicates required
*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.